BioSpace News Archive

Therachon AG (“Therachon”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions, today announced that it will present interim results from its ongoing Phase II clinical study of apraglutide at Digestive Disease Week® (DDW) in San Diego, CA.

The Epilepsy Foundation applauds the Administration for pulling back harmful provisions proposed last November that would have impeded access to life-changing, oftentimes life-saving, anticonvulsants for the 1.1 million Medicare beneficiaries living with epilepsy.

Cannabis Growth Opportunity Corporation (“CGOC”, or the “Company”) (CSE: CGOC), a cannabis-focused investment corporation with both public and private cannabis holdings, announces the company’s updated net asset value per common share (“NAV”) of $3.41 at the close of business on May 15, 2019.

Xstrahl Medical, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and dermatological conditions, is spotlighting its RADiant treatment system at the Texas Dermatology Society spring meeting on May 17th and 18th at the Marriott Marquis Hotel in Houston.

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

The “90-Day Phenomenal Energy for L.I.F.E. After 50 Program” - Wellquest Health Coaching is now open for individuals and couples 50 and better who want to achieve higher energy to get the most fun and fulfillment out of their ‘bucket list’ life experiences.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma (GBM), whose tumors have EGFR (epidermal growth factor receptor) amplification, demonstrated no survival benefit for patients receiving Depatux-M at an interim analysis.

Partnership makes Gateway first insurance company to offer incentives-based addiction recovery program leveraging most effective standalone treatment technique for substance use disorder

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will be presenting at the following events taking place in May and June.

Dale Medical Products, Inc. (Dale), the company known for its high quality, patient-friendly medical device securement solutions, is expanding its offering with its new Hold-n-Place® Catheter Securement Products.